Serologic Profile of SARS CoV2 in COVID-19 Patients With Systemic Diseases
NCT ID: NCT04530461
Last Updated: 2020-09-22
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
200 participants
OBSERVATIONAL
2020-06-01
2021-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Cardiac and Laboratory Findings in Patients With Systemic Lupus Erythematosus
NCT03179046
Natural History of Coronavirus Disease (COVID-19) in Systemic Autoimmune Diseases
NCT04690816
Immune Response to SARS-CoV-2 Vaccination in Systemic Lupus
NCT04894253
Prevalence and Seroconversion of COVID-19 in Autoimmune Diseases in Europe
NCT04397237
Regulatory BCells in Systemic Lupus Erythematosus
NCT03178721
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Patients with IgM-like antibodies will have an RT-PCR test for active infection. If the study participants will be diagnosed with COVID-19 positive during the study period, the attending physician is entitled to decide on their management based on the severity of the clinical status.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Serological test
Positive serological test of SARS Cov2
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* One of the following conditions: systemic lupus, Sjögren's syndrome, rheumatoid arthritis, inflammatory myopathies, spondyloarthritis, sarcoidosis and Behçet's disease.
* Informed consent obtained and signed
Exclusion Criteria
* Informed consent not obained
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
UR17DN02 : Autoimmune Diseases Research Unit
UNKNOWN
faida agili
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
faida agili
Director of Autoimmune Diseases Research Unit (UR17DN02) and Professor in internal medicine departement. Sponsor and Principal Investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Faida Ajili, MD
Role: STUDY_CHAIR
Military Hospital of Tunis
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Military Hospital of Tunis
Tunis, , Tunisia
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
UR17DN02-002
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.